Sort
3,198 grants matching “mrna vaccine”
Define the molecular bases for cryptococcal adaptation to host conditions by the RAM pathway
$226,500Xiaorong Lin · University Of Georgia · R21 · FY2024 · AI
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma
$226,495Owen S Fenton · Univ Of North Carolina Chapel Hill · R21 · FY2023 · EB
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma
$226,293Owen S Fenton · Univ Of North Carolina Chapel Hill · R21 · FY2024 · EB
Vaccine induction of Salmonella-specific Th1 memory cells
$225,839Stephen J McSorley · University Of California At Davis · R21 · FY2024 · AI
Serological and functional impact of COVID-19 vaccination on the maternal fetal unit and infant immunity
$225,781Rupsa Chaudhury Boelig · Thomas Jefferson University · R21 · FY2022 · HD
Defining the mechanisms by which Placenta-specific 8 (Plac8) facilitates CD8 memory formation
$225,625Wendy T Watford · University Of Georgia · R21 · FY2019 · AI
Interrogation of the sRNA regulatory network mediating virulence of Streptococcus pneumoniae
$225,525Michelle Margaret Meyer · Boston College · R21 · FY2025 · AI
Indirect Prevention of High Path Flu Zoonosis through Universal Vaccination
$225,370David E Verhoeven · Iowa State University · R21 · FY2024 · AI
Mechanisms of RNA regulation in the persistence of the AIDS pathogen Toxoplasma
$225,260Laura J Knoll · University Of Wisconsin-Madison · R21 · FY2016 · AI
A DNA nanotechnology vaccine platform for delivery and translation of HIV-1 1086C gp160 Env LNP
$225,220David Lawrence Danley · Parabon Nanolabs, Inc. · R43 · FY2019 · AI
Drug Target Validation in Trypanosoma cruzi
$225,000Roberto Docampo · University Of Georgia · R21 · FY2018 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AFRICAN SWINE FEVER (ASF) IS A HIGHLY CONTAGIOUS VIRAL DISEASE WITH MORTALITY UP TO 100% IN DOMESTIC SWINE HERDS. ASF OUTBREAKS IN EURASIA HAVE RESULTED IN TREMENDOUS ECONOMIC LOSSES TO THOSE AFFECTED COUNTRIES AND THE INTRODUCTION OF ASF INTO US SWINE INDUSTRY WOULD LEAD TO APPROXIMATELY $50 BILLION IN LOSSES. ALTHOUGH LIVE ATTENUATED VACCINES HAVE ACHIEVED PARTIAL SUCCESS, SAFETY CONCERN AND VIRAL PERSISTENCE ARE THE MAJOR ISSUES. IN THIS PROJECT, RATIONAL DESIGN AND EVALUATION OF A ASF MRNA VACCINE WILL BE CONDUCTED. THE GOAL OF THIS STUDY IS TO EVALUATE THE ENGINEERED VACCINE ANTIGENS USING LNP-MRNA FORMULATIONS FOR STIMULATION OF STRONG ANTIBODY AND T CELL IMMUNE RESPONSES.THIS WORK WILL ULTIMATELY LEAD TO DEVELOPMENT OF A MRNA VACCINE AGAINST ASFIN AID OF DISEASE CONTROL AND SWINE HEALTH.
$225,000Massachusetts Institute Of Technology · · FY2024 · National Institute of Food and Agriculture
Reverse Genetics with Rotaviruses
$225,000Robert Franklin Ramig · Baylor College Of Medicine · R21 · FY2006 · AI
THIS PROJECT UTILIZES A NON-INFECTIOUS PLANT VIRUS NANOPARTICLE FORDELIVERY OF MRNA INTO PLANTS, ALLOWING FOR A TEMPORARY CHANGE TO THE BEHAVIOR OF THE PLANTS WITHOUT PERMANENTLY ALTERING THEIR GENETIC MATERIAL. THIS CAN ALLOW PLANTS TO BE TEMPORARILY EQUIPPED TO RESIST DISEASE, OVERCOME DROUGHT CONDITIONS, OR PERFORM A NEW FUNCTION WITHOUT CHANGING ITS DNA OR CREATING REGULATORY HURDLES FOR PRODUCTION. AS THE HUMAN POPULATION CONTINUES TO GROW, IT IS IMPORTANT THAT WE HAVE MORE TECHNIQUES TO ADDRESS FOOD SECURITY, AND MITIGATING THE LOSS OF CROPS IS ONE OF THE MOST CHALLENGING ISSUES IN THIS AREA. OUR ULTIMATE GOAL IS TO STIMULATE A COMMON IMMUNE RESPONSE FOUND IN A MANY PLANTS USING THIS TECHNIQUE SO WE CAN HAVE A GENERALIZED PLANT VACCINE. IN MANY WAYS, THE PRINCIPLES OF THIS TECHNOLOGY ARE SIMILAR TO THOSE UTILIZED IN THE LIPID NANOPARTICLE COVID-19 VACCINES, BUT ADAPTED FOR USE IN PLANTS. IN THIS WORK, WE WILL FIRST WORK TO ENGINEER THE VIRUS NANOPARTICLES TO DELIVER THE APPROPRIATE MRNA BY BREAKING THEM APART, REMOVING THEIR ORIGINAL GENETIC MATERIAL, AND REPLACING IT WITH MRNA FOR THE EXPRESSION OF A GREEN FLUORESCENT PROTEIN BEFORE REASSEMBLING THE PARTICLES. WE WILL THEN INTRODUCE THESE PARTICLES TO A CULTURE OF CELLS DERIVED FROM PLANTS AS A PROOF OF CONCEPT. THE CELLS THAT UPTAKE THE VIRUSES SHOULD BEGIN TO GLOW GREEN AS THEY EXPRESS THE DELIVERED MRNA, AND WE WILL USE THIS INFORMATION TO SEE HOW EFFICIENT THE DELIVERY IS AND HOW LONG THE CELLS STAY GREEN. AFTER SOME OPTIMIZATION, WE WILL APPLY THESE NANOPARTICLES DIRECTLY TO SEVERAL PLANTS USING ABRASION, INJECTION, AND PASSIVE DIFFUSION TO SEE IF THEIR TISSUES BEGIN TO GLOW GREEN AS WELL. WITH THIS INFORMATION, WE CAN SEE IF ANY OF THE NANOPARTICLES NEED TO BE IMPROVED FOR HIGHER DELIVERY EFFICIENCY. IF THEY DO NEED TO BE MODIFIED, WE WILL ADD CELL-PENETRATING PEPTIDES TO THEIR SURFACE WHICH ALLOW THE NANOPARTICLES TO EMBED THEMSELVES IN THE CELL WALL AND MEMBRANE OF THE PLANTS FOR FASTER UPTAKE. ONCE WE HAVE SUCCESSFULLY DEMONSTRATED OUR TECHNOLOGY USING THE GREEN FLUORESCENT PROTEIN, WE WILL MOVE ON TO DELIVERING SOME TRANSCRIPTS IN OUR NANOPARTICLES THAT MAY STIMULATE AN IMMUNE RESPONSE IN PLANTS. WE WILL USE ANALYTICAL TECHNIQUES TO SEE IF THE EXPRESSION OF DIFFERENT GENES, THE METABOLISM, AND THE PROTEINS IN THESE PLANT CELLS HAVE CHANGED DUE TO THE DELIVERY OF THESE TRANSCRIPTS. IF THE RESULTS INDICATE WE MAY HAVE ACTIVATED AN IMMUNE RESPONSE IN CELL CULTURE, WE WILL ADVANCE TO WHOLE PLANT DELIVERY AND USE THE SAME ANALYTICAL TECHNIQUES, IMAGING, AND HISTOLOGY TO DETERMINE THE EFFICIENCY OF OUR TECHNOLOGY. IT IS OUR HOPE THAT THIS TECHNOLOGY WILL ENABLE BROAD PROTECTION AGAINST MANY DIFFERENT PATHOGENS USING THE HIGHLY CONSERVED SYSTEMIC ACQUIRED RESISTANCE PATHWAY FOUND IN A LARGE NUMBER OF PLANTS. SPECIFICALLY, WE HOPE THIS CAN BE USED AS AN ON-DEMAND VACCINE FOR PLANTS WHEN INFECTION IS DETECTED SOMEWHERE IN THE FIELD TO PROTECT THE REST OF THE CROPS, WHICH WOULD SIMULTANEOUSLY PREVENT CROP LOSSES AND IMPROVE THE ECONOMIC OUTLOOK OF FARMERS IN DISEASE-PRONE AREAS.
$225,000University Of California, San Diego · · FY2022 · National Institute of Food and Agriculture
A Novel Approach to Purifying iPSC Derived Cell Cultures
$225,000Scott A Tenenbaum · Hocuslocus, Inc. · R41 · FY2015 · GM
Identification of the ribosomal target of Shiga-like toxins
$224,908Nilgun E Tumer · Rutgers, The State Univ Of N.J. · R21 · FY2007 · AI
Cholera Pathogenesis, mucinase activity and motility
$224,878Jorge Antonio Benitez · Morehouse School Of Medicine · R01 · FY2006 · AI
Adjuvant effect of physical exercise on immune response to COVID-19 vaccination and interactions with stress
$224,877Marian L Kohut · Iowa State University · R21 · FY2023 · AI
Cholera Pathogenesis, mucinase activity and motility
$224,762Morehouse School Of Medicine · R01 · FY2005 · AI
Stable Gene Transfer by RNA Delivery
$224,634Leah Justine Hogdal · B-Mogen Biotechnologies, Inc. · R43 · FY2017 · HL
Lnc-PINK regulation of innate immunity in lung epithelial cells
$224,400Lin Liu · Oklahoma State University Stillwater · R21 · FY2021 · AI
Screening for LXR agonists-inhibitors of brain amyloidosis and inflammation
$224,241Iliya Lefterov · University Of Pittsburgh At Pittsburgh · R21 · FY2008 · AG
STRUCTURE AND ASSEMBLY OF VIRUSES
$223,653Harvard University · R01 · FY2000 · CA
Pioneering Precision Medicine Approaches for Immune Control of Pediatric HIV-1 Infection
$223,467Mathias Lichterfeld · Harvard School Of Public Health · P01 · FY2021 · HD
Systems biological assessment of innate and adaptive immunity to vaccination
$223,238Bali Pulendran · Stanford University · U19 · FY2023 · AI